Literature DB >> 28087162

miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation.

Laurent Ehrlich1, Chad Hall2, Julie Venter3, David Dostal4, Francesca Bernuzzi5, Pietro Invernizzi5, Fanyin Meng6, Jerome P Trzeciakowski4, Tianhao Zhou3, Holly Standeford7, Gianfranco Alpini8, Terry C Lairmore2, Shannon Glaser9.   

Abstract

Menin (MEN1) is a tumor-suppressor protein in neuroendocrine tissue. Therefore, we tested the novel hypothesis that menin regulates cholangiocarcinoma proliferation. Menin and miR-24 expression levels were measured in the following intrahepatic and extrahepatic cholangiocarcinoma (CCA) cell lines, Mz-ChA-1, TFK-1, SG231, CCLP, HuCCT-1, and HuH-28, as well as the nonmalignant human intrahepatic biliary line, H69. miR-24 miRNA and menin protein levels were manipulated in vitro in Mz-ChA-1 cell lines. Markers of proliferation and angiogenesis (Ki-67, vascular endothelial growth factors A/C, vascular endothelial growth factor receptors 2/3, angiopoietin 1/2, and angiopoietin receptors 1/2) were evaluated. Mz-ChA-1 cells were injected into the flanks of nude mice and treated with miR-24 inhibitor or inhibitor scramble. Menin expression was decreased in advanced CCA specimens, whereas miR-24 expression was increased in CCA. Menin overexpression decreased proliferation, angiogenesis, migration, and invasion. Inhibition of miR-24 increased menin protein expression while decreasing proliferation, angiogenesis, migration, and invasion. miR-24 was shown to negatively regulate menin expression by luciferase assay. Tumor burden and expression of proliferative and angiogenic markers was decreased in the miR-24 inhibited tumor group compared to controls. Interestingly, treated tumors were more fibrotic than the control group. miR-24-dependent expression of menin may be important in the regulation of nonmalignant and CCA proliferation and may be an additional therapeutic tool for managing CCA progression.
Copyright © 2017 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28087162      PMCID: PMC5389363          DOI: 10.1016/j.ajpath.2016.10.021

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

1.  Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1.

Authors:  S Saijyo; T Kudo; M Suzuki; Y Katayose; M Shinoda; T Muto; K Fukuhara; T Suzuki; S Matsuno
Journal:  Tohoku J Exp Med       Date:  1995-09       Impact factor: 1.848

2.  Characteristic miR-24 Expression in Gastric Cancers among Atomic Bomb Survivors.

Authors:  Yutaka Naito; Naohide Oue; Trang T B Pham; Manabu Yamamoto; Megumu Fujihara; Teruyoshi Ishida; Shoichiro Mukai; Kazuhiro Sentani; Naoya Sakamoto; Eisuke Hida; Hiroki Sasaki; Wataru Yasui
Journal:  Pathobiology       Date:  2015-05-30       Impact factor: 4.342

3.  Diagnostic and prognostic significance of serum miR-24-3p in HBV-related hepatocellular carcinoma.

Authors:  Fan-Long Meng; Wei Wang; Wei-Dong Jia
Journal:  Med Oncol       Date:  2014-08-17       Impact factor: 3.064

4.  Conditional deletion of menin results in antral G cell hyperplasia and hypergastrinemia.

Authors:  Natalia A Veniaminova; Michael M Hayes; Jessica M Varney; Juanita L Merchant
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-07-05       Impact factor: 4.052

5.  A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium.

Authors:  M Miyagiwa; T Ichida; T Tokiwa; J Sato; H Sasaki
Journal:  In Vitro Cell Dev Biol       Date:  1989-06

6.  Biliary adenocarcinoma. Characterisation of three new human tumor cell lines.

Authors:  A Knuth; H Gabbert; W Dippold; O Klein; W Sachsse; D Bitter-Suermann; W Prellwitz; K H Meyer zum Büschenfelde
Journal:  J Hepatol       Date:  1985       Impact factor: 25.083

7.  Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells.

Authors:  Y Shimizu; A J Demetris; S M Gollin; P D Storto; H M Bedford; S Altarac; S Iwatsuki; R B Herberman; T L Whiteside
Journal:  Int J Cancer       Date:  1992-09-09       Impact factor: 7.396

8.  Menin promotes hepatocellular carcinogenesis and epigenetically up-regulates Yap1 transcription.

Authors:  Bin Xu; Shan-Hua Li; Rong Zheng; Shu-Bin Gao; Li-Hong Ding; Zhen-Yu Yin; Xiao Lin; Zi-Jie Feng; Sheng Zhang; Xiao-Min Wang; Guang-Hui Jin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-07       Impact factor: 11.205

9.  JunD reduces tumor angiogenesis by protecting cells from oxidative stress.

Authors:  Damien Gerald; Edurne Berra; Yves M Frapart; Denise A Chan; Amato J Giaccia; Daniel Mansuy; Jacques Pouysségur; Moshe Yaniv; Fatima Mechta-Grigoriou
Journal:  Cell       Date:  2004-09-17       Impact factor: 41.582

10.  Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth.

Authors:  Gianfranco Alpini; Pietro Invernizzi; Eugenio Gaudio; Julie Venter; Shelley Kopriva; Francesca Bernuzzi; Paolo Onori; Antonio Franchitto; Monique Coufal; Gabriel Frampton; Domenico Alvaro; Sum P Lee; Marco Marzioni; Antonio Benedetti; Sharon DeMorrow
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

View more
  13 in total

Review 1.  A Review of the Scaffold Protein Menin and its Role in Hepatobiliary Pathology.

Authors:  Laurent Ehrlich; Chad Hall; Fanyin Meng; Terry Lairmore; Gianfranco Alpini; Shannon Glaser
Journal:  Gene Expr       Date:  2017-04-28

Review 2.  Epigenetic regulation by the menin pathway.

Authors:  Zijie Feng; Jian Ma; Xianxin Hua
Journal:  Endocr Relat Cancer       Date:  2017-08-15       Impact factor: 5.678

3.  Inhibition of microRNA-24 increases liver fibrosis by enhanced menin expression in Mdr2-/- mice.

Authors:  Chad Hall; Laurent Ehrlich; Fanyin Meng; Pietro Invernizzi; Francesca Bernuzzi; Terry C Lairmore; Gianfranco Alpini; Shannon Glaser
Journal:  J Surg Res       Date:  2017-05-11       Impact factor: 2.192

Review 4.  The miR-23-27-24 cluster: an emerging target in NAFLD pathogenesis.

Authors:  Lin Ru; Xiao-Mei Wang; Jun-Qi Niu
Journal:  Acta Pharmacol Sin       Date:  2021-12-10       Impact factor: 7.169

Review 5.  NcRNAs and Cholangiocarcinoma.

Authors:  Zheng Wangyang; Ji Daolin; Xu Yi; Li Zhenglong; Huang Lining; Cui Yunfu; Jiang Xingming
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

Review 6.  Recent Advances in Understanding Cholangiocarcinoma.

Authors:  Lindsey Kennedy; Laura Hargrove; Jennifer Demieville; Nicole Francis; Rowan Seils; Sara Villamaria; Heather Francis
Journal:  F1000Res       Date:  2017-10-09

Review 7.  Role of Non-Coding RNAs in the Progression of Liver Cancer: Evidence from Experimental Models.

Authors:  April O'Brien; Tianhao Zhou; Christopher Tan; Gianfranco Alpini; Shannon Glaser
Journal:  Cancers (Basel)       Date:  2019-10-25       Impact factor: 6.639

8.  The Effect of Methylselenocysteine and Sodium Selenite Treatment on microRNA Expression in Liver Cancer Cell Lines.

Authors:  Gábor Lendvai; Tímea Szekerczés; Endre Kontsek; Arun Selvam; Attila Szakos; Zsuzsa Schaff; Mikael Björnstedt; András Kiss
Journal:  Pathol Oncol Res       Date:  2020-07-12       Impact factor: 3.201

9.  MiR-24-3p regulates cell proliferation and milk protein synthesis of mammary epithelial cells through menin in dairy cows.

Authors:  Cao Qiaoqiao; Honghui Li; Xue Liu; Zhengui Yan; Meng Zhao; Zhongjin Xu; Zhonghua Wang; Kerong Shi
Journal:  J Cell Physiol       Date:  2018-09-17       Impact factor: 6.384

10.  MiR-15a/miR-16-1 expression inversely correlates with cyclin D1 levels in Men1 pituitary NETs.

Authors:  Kate E Lines; Paul J Newey; Christopher J Yates; Mark Stevenson; Rebecca Dyar; Gerard V Walls; Mike R Bowl; Rajesh V Thakker
Journal:  J Endocrinol       Date:  2018-09-01       Impact factor: 4.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.